Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis – Overview
Liver Cirrhosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis – Companies Involved in Therapeutics Development
Advantagene Inc
AlfaSigma SpA
Bristol-Myers Squibb Co
Galectin Therapeutics Inc
Gilead Sciences Inc
Grifols SA
International Stem Cell Corp
Mina Therapeutics Ltd
Novo Nordisk AS
Pharmicell Co Ltd
Promethera Biosciences SA
Rohto Pharmaceutical Co Ltd
Versantis AG
VESSL Therapeutics Ltd
Liver Cirrhosis – Drug Profiles
7-E – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADR-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
albumin (human) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-800 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belapectin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986263 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-LC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MMP8 for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ZSCAN4 for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-9931 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegbelfermin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit C/EBP-Beta for Gastrointestinal and Respiratory Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin SSD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis – Dormant Projects
Liver Cirrhosis – Discontinued Products
Liver Cirrhosis – Product Development Milestones
Featured News & Press Releases
Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Liver Cirrhosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Liver Cirrhosis - Pipeline by Advantagene Inc, H2 2019
Liver Cirrhosis - Pipeline by AlfaSigma SpA, H2 2019
Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2019
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2019
Liver Cirrhosis - Pipeline by Grifols SA, H2 2019
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H2 2019
Liver Cirrhosis - Pipeline by Mina Therapeutics Ltd, H2 2019
Liver Cirrhosis - Pipeline by Novo Nordisk AS, H2 2019
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H2 2019
Liver Cirrhosis - Pipeline by Promethera Biosciences SA, H2 2019
Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, H2 2019
Liver Cirrhosis - Pipeline by Versantis AG, H2 2019
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H2 2019
Liver Cirrhosis - Dormant Projects, H2 2019
Liver Cirrhosis - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Liver Cirrhosis, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products by Targets, H2 2019 17
Number of Products by Stage and Targets, H2 2019 17
Number of Products by Mechanism of Actions, H2 2019 19
Number of Products by Stage and Mechanism of Actions, H2 2019 19
Number of Products by Routes of Administration, H2 2019 21
Number of Products by Stage and Routes of Administration, H2 2019 21
Number of Products by Top 10 Molecule Types, H2 2019 23
Number of Products by Stage and Top 10 Molecule Types, H2 2019 23
【掲載企業】
Advantagene Inc
AlfaSigma SpA
Bristol-Myers Squibb Co
Galectin Therapeutics Inc
Gilead Sciences Inc
Grifols SA
International Stem Cell Corp
Mina Therapeutics Ltd
Novo Nordisk AS
Pharmicell Co Ltd
Promethera Biosciences SA
Rohto Pharmaceutical Co Ltd
Versantis AG
VESSL Therapeutics Ltd